key: cord-0802479-bg1m8r6z
authors: Xia, Lu; Chen, Jun; Friedemann, Thomas; Yang, Zongguo; Ling, Yun; Liu, Xuhui; Lu, Shuihua; Li, Tao; Song, Zhigang; Huang, Wei; Lu, Yunfei; Schröder, Sven; Lu, Hongzhou
title: The course of mild and moderate Covid-19 infections – the unexpected long-lasting challenge
date: 2020-07-23
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofaa286
sha: 84d41f8e01de9d146cee2e29f07ce05de31c5661
doc_id: 802479
cord_uid: bg1m8r6z

BACKGROUND: The course of disease in mild and moderate COVID-19 has many implications for mobile patients, such as the risk of spread of the infection, the precautions taken and the investigations targeted at preventing transmission. METHODS: 331 adults were hospitalized from 21 January to 22 February 2020 and classified as severe (10%) and critical (4.8%) cases; 1.5% died. 282 (85.2%) mild or moderate cases were admitted to regular wards. Epidemiological, demographic, clinical, chest CT scan, laboratory, treatment and outcome data from patient records were analyzed retrospectively. RESULTS: Patients were symptomatic for 9.82±5.75 (1–37) days. Pulmonary involvement was demonstrated on a chest CT scan in 97.9% of cases. It took 16.81±8.54 (3–49) days from the appearance of the first symptom until 274 patients tested virus-negative in NP swabs, blood, urine, and stool. And, 234 (83%) patients were already asymptomatic for 9.09±7.82 (1–44) days. Subsequently, 131 patients were discharged. 169 remained in hospital, these patients tested virus-free and were clinically asymptomatic, because of widespread persisting or increasing pulmonary infiltrates. Hospitalization took 16.24±7.57 (2–47) days – from the first symptom to discharge the time interval was 21.37±7.85 (3–52) days. CONCLUSIONS: With an asymptomatic phase, disease courses are unexpectedly long until the stage of virus negativity. NP swabs are not reliable in later stages of COVID-19. Pneumonia outlasts virus-positive tests if sputum is not acquired. Imminent pulmonary fibrosis in high-risk groups demands follow-up examinations. Investigation of promising antiviral agents should heed the specific needs of mild and moderate COVID-19 patients.

From the end of 2019, the new coronavirus pneumonia COVID-19 spread from Wuhan 1, 2 within 30 days to the rest of Mainland China 3 . By 11 March 2020, it was declared a pandemic 4 , demonstrating its high infectiousness. The Coronavirus Study Group named it SARS-CoV-2 5 , but Chinese virologists recommended the name HoV-19 because it is distinct from SARS-CoV 6 . Fever, cough, sputum, and fatigue are the most prominent symptoms.

Upper respiratory tract symptoms are infrequent 7, 8 . To date, the mortality rate is lower than of prior known coronavirus diseases SARS or MERS 9 . Mild or moderate COVID-19

represents the majority (81%) of cases 10 . However, severe courses of infection occur in 14% and are critical in 5% of cases 10 . The classification 11 is shown in Table 1 .

Pneumonia is common in COVID-19 and can occur even in patients with few symptoms.

Some studies found viral pneumonia in 100% of all symptomatic patients 12 and even in 50% of asymptomatic cases 13 . On a chest CT scan, COVID-19 is characterized by rapid evolution from focal unilateral to diffuse bilateral ground-glass opacities that progress to or co-exist with consolidations within 1-3 weeks 14 .

Treatments in this study population were based on recommendations released by the General Office of Chinese National Health Commission 11 . Lopinavir/ritonavir is an HIV medication, which has been effective for both in vitro and clinical studies against SARS 15 .

The antimalarial substance chloroquine and the antiviral influenza medication Umifenovir were found to be effective in vitro against SARS-COV-2 16 . ShuFengJieDu (SFJD) is the herbal first choice Chinese medicine against influenza in China. It can alleviate acute lung inflammatory injury 17 and protect against it by suppressing the MAPK/NF-κB pathway 18 in rodents.

Many studies focus on high-risk patients who have higher mortality rates 19 ; they also focus on intensive care management 20 , special groups 7 or co-morbidities 9 . This study focuses on A c c e p t e d M a n u s c r i p t 5 the course of mild and moderate cases because these represent the majority of mobile patients who have a high risk of transmission of the disease. The analyzed dataset of this study is unique because it was acquired in an early phase of the epidemic where there was the capacity to hospitalize patients with low-grade symptoms. With the worldwide spread of the disease, these patients are now candidates for home quarantine. Hence, defining disease stages, and the identification of its determining factors are instructive for the definition of standards for home quarantine. The necessary clinical and laboratory observations are required and, for personal safety, adequate protective measures must be implemented to prevent further spread of the disease. So far, less attention has been focused on the follow-up of clinically recovered patients.

We collected data from 331 adults with confirmed COVID-19, who were hospitalized in Shanghai Public Health Clinic Center from 21 January to 22 February 2020. The cohort study protocol was approved by the Shanghai Public Health Clinic Center Ethics Committee (YJ-2020-S015-01) and written informed consent was obtained. Patients were classified as mild, moderate, severe, or critically ill 11 . Thirty-three (10%) of these patients were of the severe type. Sixteen patients (4.8%), of whom five patients (1.5%) died, were critically ill and had to be treated on the Intensive Care Unit. The data of 282 (85.2%) patients submitted to regular care inpatient wards with mild (n = 6, 1.8%) or moderate (n = 276, 83.1%) symptoms on admission were evaluated.

A c c e p t e d M a n u s c r i p t 6

We obtained epidemiological, demographic, clinical, laboratory, chest CT scans, as well as outcome data from patients' medical records (CDCs reporting forms). If the epidemiological data were not clear enough, a telephone or face-to-face interview with patients or contacts were conducted. Clinical outcomes were followed up to 24 March 2020. Laboratory confirmation of COVID-19 was done by the Shanghai CDC. Clinical symptoms were monitored daily by the attending physicians. Blood tests, including WBC, platelets, hemoglobin, ALT, AST, total bilirubin, direct bilirubin, blood urinary nitrogen, creatinine, CD4, CD8, CD4/CD8 ratio, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin (PCT) were taken at admission and before discharge.

The nasopharyngeal swabs, oropharyngeal swabs, urine, stool (once every 3 days), serum Co., Ltd., 2.08 g, t.i.d.), Darunavir and Cobicistat tablets (Janssen Ortho, LLC, one tablet, q.d).

Supportive medications: vitamin C (Tianjin Lisheng Pharmaceutical Co., Ltd, two tablets,

A c c e p t e d M a n u s c r i p t 8

Statistical analysis was performed using OriginPro 9.0 (OriginLab Corporation, Northampton, USA). Data were presented as mean ± standard deviation (SD). Significant differences between the means were determined using the Student's t test and Wilcoxon test. P < 0.05 was considered significant.

The study consisted of 141 female patients (50%), 141 males (50%). Mean age was Table 2 summarizes the chest CT scan findings. Supplementary Figures 1 and 2 show chest CT scans in the course of the disease in two cases.

A c c e p t e d M a n u s c r i p t Figure 1 describes the course of COVID-19 infection and Table 3 compares the duration of each period. cases.

The results of this study confirm prior reports in relation to symptomatology 8 and case severity as related to age 7 . However, patients had a lower frequency of severe infection (9.9%) and less-deadly cases (1.5%) occurred in comparison with prior reports 10 . In contrast to mild and moderate symptomatology, 276 of 282 (97.7%) patients had typical ground-glass opacification with or without consolidative abnormalities on chest CT scans, representing a viral pneumonia 12, 14, 23 . However, pleural effusions were common (13.5%), which were previously described as rare (4%) 11, 24 .

The course of COVID-19 is determined by the following characteristics: the incubation period, the symptomatic phase, an asymptomatic phase until virus detection becomes A c c e p t e d M a n u s c r i p t 13 negative, and by the features of disease activity in chest CT scans. Despite the low severity of the described cases, the course of the disease was remarkably long. Clinical pilot studies showed that SFJD might, on its first appearance, positively influence the symptoms and the time to yield virus negativity 45, 46 ; and at the least, one ingredient of SFJD taxifolin 47 showed high positive binding at the main protease of the virus. The role of hydroxychloroquine remains a matter of debate. A single study showed positive results 48 while large observational studies showed no effectiveness 49 , indicating the need for further confirmation. Furthermore, the drug has potential detrimental effects 50 .

While moderate and mild cases represent the absolute majority of cases, studies should also focus on the development of well-tolerable drugs that influence the symptoms and the course of mild and moderate patients in order to avoid long-term pulmonary damage.

The study had certain limitations. Data analysis was retrospective and did not fulfill the criteria of a randomized controlled study. However, all patients had similar severity of the A c c e p t e d M a n u s c r i p t 16 disease, so examination of real-life situations provided useful information. Furthermore, we did not get results from bronchoalveolar fluids. Testing was usually limited to patients with severe illness or those undergoing mechanical ventilation 51 .

In conclusion, the 21.37±7.85 (3-52) day-long course from first symptom(s) to hospital dismission of mild and moderate cases of COVID-19 is unexpectedly long and has potential

pitfalls. An asymptomatic phase is problematic until virus negativity with an associated unclear level of infection. While the virus moves quickly from the NP region to the lungs and intestines, detection in NP swabs is not reliable in later stages of the disease and potential infectiousness from stool or expectoration has to be further evaluated.. Relatively mild symptoms obscure the fact that these patients mostly suffer from viral pneumonia. A c c e p t e d M a n u s c r i p t M a n u s c r i p t

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

Characteristics of COVID-19 infection in Beijing

WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 -11

Severe acute respiratory syndrome-related coronavirus: The species and its viruses -a statement of the Coronavirus Study Group

A distinct name is needed for the new coronavirus

Managing neonates with respiratory failure due to SARS-CoV-2

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Comorbidities and multi-organ injuries in the treatment of COVID-19

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

General Office of Chinese National Health Commission. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia Trial Version 7. Chinese, English Translation organized by WHO China Office

Clinical Characteristics of 138 Hospitalized Patients With

Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Shufeng Jiedu Capsules Alleviate Lipopolysaccharide-Induced Acute Lung Inflammatory Injury via Activation of GPR18 by Verbenalin

Shufeng Jiedu Capsule protect against acute lung injury by suppressing the MAPK/NF-κB pathway

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations

Novel Coronavirus (2019-nCoV) Pneumonia

Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study

Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT

Presumed Asymptomatic Carrier Transmission of COVID-19

Viral load of SARS-CoV-2 in clinical samples

Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

Respiratory virus shedding in exhaled breath and efficacy of face masks

Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing

Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases

SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts

Radiology Perspective of Coronavirus Disease 2019 (COVID-19): Lessons From Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome

Long-term consequences in lung and bone associated with hospitalacquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study

Follow-up chest radiographic findings in patients with MERS-CoV after recovery

Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Analysis of the value of Shufeng Jiedu capsules combined with Abidol in the treatment of mild COVID-2019 (Chinese)

Observation on the clinical effect of Shufeng Jiedu Capsule combined with Arbidol Hydrochloride Capsules in the treatment of COVID-19

Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 687 Million Compounds

lingyun@shphc.org.cn Xuhui Liu: liuxuhui@shphc.org.cn

lushuihua@shphc.org.cn Tao Li: litao@shphc.org.cn

Zhigang Song: songzhigang@shphc.org.cn

Chinese medicine administration of Shanghai Health Protection Committee, Chinese medicine prevention and treatment of novel coronavirus pneumonia emergency special subject, Chinese medicine treatment new coronavirus pneumonitis real world clinical observation research

The study protocol was approved by the SPHCC Ethics Committee (YJ-2020-S015-01) Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data

and decision(s) to submit the manuscript for publication

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t